BioXcel Therapeutics Inc BTAI
News
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation
BioXcel Therapeutics Shares Sink After Weak 3Q
BioXcel Therapeutics shares pop after audit of Alzheimer's trial data